#2 - Spiro Rombotis, CEO at Cyclacel Pharmaceuticals

Our Guest: #2 - Spiro Rombotis, CEO at Cyclacel PharmaceuticalsWhat you'll get out of this episode:Rombotis's background and an overview of CyclacelWhich part of the cell cycle they're targeting?What their leading candidates are, and the current clinical trial statuses of each.What makes their CDK inhibitor strategy unique compared to other biopharmaceutical companies?Their PLK1 programNear-term milestones and what's next?Our sponsors for this episode are Sage Growth PartnersSage Growth Partners accelerates commercial success for healthcare organizations through a singular focus on growth. The company helps its clients thrive amid the complexities of a rapidly changing marketplace with deep domain expertise and an integrated application of research, strategy, and marketing. For more information, please go to www.sage-growth.com & follow Sage Growth Partners on social media - @sagegrowthpartners